Treating Castration-Resistant Prostate Cancer

Opinion
Video

Medical oncologists provide clinical insights on treatment paradigms for patients with castration-resistant prostate cancer, highlighting how next-generation sequencing informs treatment decisions.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Related Content
FDA OKs Leuprolide Mesylate 3-Month Formulation in Advanced Prostate Cancer

FDA OKs Leuprolide Mesylate 3-Month Formulation in Advanced Prostate Cancer

Ariana Pelosci;Tim Cortese
September 9th 2025
Article
Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
September 9th 2025
Podcast
The FDA has accepted a new drug application for the prostate-specific membrane antigen PET imaging agent.

FDA Accepts NDA for New Formulation of PSMA PET Injection in Prostate Cancer

Tim Cortese
September 9th 2025
Article
1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
September 9th 2025
Podcast
Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.

Talazoparib Combo Significantly Improves Overall Survival in Metastatic CRPC

Roman Fabbricatore
September 9th 2025
Article
No dose-limiting toxicities or unexpected adverse effects occurred with carotuximab/apalutamide in metastatic castration-resistant prostate cancer.

Carotuximab/Apalutamide Shows Tolerability in Metastatic CRPC

Roman Fabbricatore
September 9th 2025
Article